Clinical Edge Journal Scan

Migraine history raises susceptibility to Alzheimer’s disease


 

Key clinical point: The risk of developing Alzheimer’s disease (AD) dementia is significantly higher in individuals with vs without migraine, with younger age, obesity, and chronic migraine being significant risk factors for AD dementia among individuals with migraine.

Major finding: A prior history of migraine is a significant risk factor for AD dementia (hazard ratio [HR] 1.32; 95% CI 1.30-1.35). The risk was prominently higher among individuals with vs without migraine who were younger (HR 1.58; 95% CI 1.52-1.64) and had obesity (HR 1.39; 95% CI 1.35-1.43) and among those with chronic vs episodic migraine (CM HR 1.48, 95% CI 1.44-1.52; vs EM HR 1.26, 95% CI 1.27-1.29).

Study details: This retrospective, nationwide cohort study included individuals without (n = 5,863,348) and with (n = 212,836) migraine.

Disclosures: This study was supported by grants from the National Research Foundation funded by the Ministry of Education, the Technology Development Program funded by the Ministry of SMEs and Startups (Korea), and others. The authors declared no conflicts of interest.

Source: Kim J et al. Association between migraine and Alzheimer’s disease: A nationwide cohort study. Front Aging Neurosci. 2023;15:1196185 (May 25). doi: 10.3389/fnagi.2023.1196185

Recommended Reading

Update on Migraine Prevention 2023
Migraine ICYMI
Omega-3 supplementation may improve inflammatory markers in episodic migraine
Migraine ICYMI
Commentary: CGRP medications, COVID-19, and menopause in patients with migraine, June 2023
Migraine ICYMI
New diagnostic criteria for menstrual migraine
Migraine ICYMI
Concomitant oral preventive treatment may dampen response in chronic migraine treated with onabotulinumtoxinA
Migraine ICYMI
Efficacy of galcanezumab after 1 week of treatment for migraine predicts responders at 3 months
Migraine ICYMI
Perimenstrual migraine attacks are exclusively migraine attacks without aura, recommends study
Migraine ICYMI
Real-world data show benefits of anti-CGRP mAb in migraine patients age ≥ 65 years
Migraine ICYMI
Fremanezumab switch may benefit migraine patients who are not responding to anti-CGRP mAb
Migraine ICYMI
Opioid use more frequent in patients with chronic migraine
Migraine ICYMI